ASCO Cancer Drug Valuation Tool Will Incorporate Patient Preferences
This article was originally published in The Pink Sheet Daily
Executive Summary
Software that physicians and patients could use to inform value assessments for cancer drugs could be available within a year.
You may also be interested in...
Cancer Drug Prices Inconsistent With Value Scores From NCCN Prescribing Tool
Research presented at the American Society for Clinical Oncology annual meeting evaluates cancer drug costs and benefits using two value frameworks meant to assist physicians and patients in treatment decisions.
Oncology Drug Prices In US, Europe Misaligned With Clinical Value Assessments
Study's finding is somewhat surprising for Europe, given the greater national involvement in drug prices in the region; ASCO and ESMO value frameworks don't appear to drive oncology pricing decisions regardless of the reimbursement system.
Valuing Drugs In The US: How We're Doing And What's Ahead
Numerous value frameworks launched over the past few years have encouraged acceptance of cost effectiveness assessments in the US and ICER's influence in the field is growing. Employers may be the next group to promote the concept.